Title: Correlation between vitamin D status and Serum lipid profile parameters in CAD Patients Attending a Tertiary Hospital

Authors: Dr Vivek Jain, Dr Rajeeb Kalita

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i12.48

Abstract

Cardiovascular disease(CVD) is consists of variety of heart disease, illnesses and events that impact the heart & circulatory system, including high blood pressure & coronary artery disease. Our aim was to the study serum vitamin D levels in patients with proven CAD attending cardiology clinic of SAIMS hospital and to compare it with control subjects and it’s out come. Our study add input to previous existing evidence suggesting that low vitamin D levels may be an independent, potentially modifiable cardiovascular risk factor. We observed that high prevalence of hypovitaminosis D in cases with angiographically documented CAD. Thus we can conclude that serum Vitamin D estimation may be considered as an important surrogate marker for screening and prevention of CAD to improve the outcome which needs further exploration.

Keywords: 25(OH) Vitamin D, Lipid Profile and coronary artery disease.

References

  1. Organization, W.H. World Health Statistics 2011; World Health Organization: Geneva, Switzerland, 2011.
  2. American Heart Association Heart Disease & Stroke Statistics, 2008.
  3. Bouillon, R.; Carmeliet, G.; Verlinden, L.; van Etten, E.; Verstuyf, A.; Luderer, H.F.; Lieben, L.; Mathieu, C.; Demay, M. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr. Rev. 2008, 29, 726–776.
  4. Souberbielle, J.-C.; Body, J.-J.; Lappe, J.M.; Plebani, M.; Shoenfeld, Y.; Wang, T.J.; Bischoff-Ferrari, H.A.; Cavalier, E.; Ebeling, P.R.; Fardellone, P.; et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun. Rev. 2010, 9, 709–715.
  5. Muscogiuri, G.; Sorice, G.P.; Ajjan, R.; Mezza, T.; Pilz, S.; Prioletta, A.; Scragg, R.; Volpe, S.L.; Witham, M.D.; Giaccari, A. Can vitamin D deficiency cause diabetes and cardiovascular diseases? Present evidence and future perspectives. Nutr.Metab.Cardiovasc. Dis. 2012, 22, 81–87.
  6. Pilz, S.; Tomaschitz, A.; März, W.; Drechsler, C.; Ritz, E.; Zittermann, A.; Cavalier, E.; Pieber, T.R.; Lappe, J.M.; Grant, W.B.; et al. Vitamin D, cardiovascular disease and mortality. Clin.Endocrinol.(Oxf.) 2011, 75, 575–584.
  7. Organization, W.H. World Health Statistics 2012; World Health Organization: Geneva, Switzerland, 2012.
  8. Burgaz, A.; Orsini, N.; Larsson, S.C.; Wolk, A. Blood 25-hydroxyvitamin D concentration and hypertension: A meta-analysis. J. Hypertens. 2011, 29, 636–645.
  9. Zittermann, A.; Iodice, S.; Pilz, S.; Grant, W.B.; Bagnardi, V.; Gandini, S. Vitamin D deficiency and mortality risk in the general population: A meta-analysis of prospective cohort studies. Am. J. Clin. Nutr. 2012, 95, 91–100.
  10. Grandi, N.C.; Breitling, L.P.; Brenner, H. Vitamin D and cardiovascular disease: Systematic review and meta-analysis of prospective studies. Prev. Med. 2010, 51, 228–233.
  11. Wang, L.; Song, Y.; Manson, J.E.; Pilz, S.; März, W.; Michaëlsson, K.; Lundqvist, A.; Jassal, S.K.; Barrett-Connor, E.; Zhang, C.; et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: A meta-analysis of prospective studies. Circ. Cardiovasc. Qual. Outcomes 2012, 5, 819–829.
  12. Slomski, A. IOM endorses vitamin D, calcium only for bone health, dispels deficiency claims. JAMA 2011, 305, 453–456.
  13. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Guidelines for preventing and treating vitamin d deficiency and insufficiency revisited. J. Clin. Endocrinol.Metab. 2012, 97, 1153–1158.
  14. Mithal, A.; Wahl, D.A.; Bonjour, J.-P.; Burckhardt, P.; Dawson-Hughes, B.; Eisman, J.A.; El-Hajj Fuleihan, G.; Josse, R.G.; Lips, P.; Morales-Torres, J. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos. Int. 2009, 20, 1807–1820.
  15. Van Schoor, N.M.; Lips, P. Worldwide vitamin D status. Best Pract. Res. Clin. Endocrinol.Metab. 2011, 25, 671–680.
  16. Macdonald, H.M.; Mavroeidi, A.; Fraser, W.D.; Darling, A.L.; Black, A.J.; Aucott, L.; O’Neill, F.; Hart, K.; Berry, J.L.; Lanham-New, S.A.; et al. Sunlight and dietary contributions to the seasonal vitamin D status of cohorts of healthy postmenopausal women living at northerly latitudes: A major cause for concern? Osteoporos. Int. 2011, 22, 2461–2472.
  17. The global statistic on non communicable disease report 2011 WHO.
  18. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF: Vitamin D deficiency an important,common, and easily treatable cardiovascular risk factor? J Am CollCardiol 52:1949-1956, 2008.
  19. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B,Mehrotra R, Norris K: Prevalence of cardiovascular risk factors and the serum levels of25-hydroxyvitamin D in the United States: data from the Third National Health andNutrition Examination Survey. Arch Intern Med 167:1159-1165, 2007.
  20. Zittermann A, Schleithoff SS, Koerfer R: Putting cardiovascular disease andvitamin D insufficiency into perspective. Br J Nutr 94:483-492, 2005.
  21. Holick MF: Vitamin D deficiency. N Engl J Med 357:266-281, 2007.
  22. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, wson-Hughes B:Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiplehealth outcomes. Am J ClinNutr 84:18-28,
  23. 2006 Alpert et al., 2000; Martins etal., 1996.
  24. Bertinchant et al., 1996; Lewandrowski et al., 2002; Sluss, 2006; Wu et al.,1999.
  25. Jorde, R.; Grimnes, G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog. Lipid Res. 2011, 50, 303–312.
  26. Jaimungal, S.; Wehmeier, K.; Mooradian, A.D.; Haas, M.J. The emerging evidence for vitamin D-mediated regulation of apolipoprotein AI synthesis.Nutr. Res. 2011, 31, 805–812.
  27. Skaaby, T.; Husemoen, L.L.N.; Pisinger, C.; Jørgensen, T.; Thuesen, B.H.; Fenger, M.; Linneberg, A. Vitamin D status and changes in cardiovascular risk factors: A prospective study of a general population. Cardiology 2012, 123, 62–70
  28. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S,Kannel WB. (1986) Incidence of coronary heart disease and lipoproteincholesterol levels: the Framingham Study. JAMA.256(20):2835-2838(55).
  29. Sharrett A, Ballantyne C, Coady S, Heiss G, Sorlie P, Catellier D,Patsch W. (2001) Coronary Heart Disease Prediction From LipoproteinCholesterol Levels, Triglyce-rides, Lipoprotein(a), Apolipoproteins A-I and B, andHDL Density Subfractions. The Atherosclerosis Risk in Communities (ARIC)Study. Circulation.;104:1108-1113 (doi: 10.1161/hc3501.095214).
  30. Hopkins P, Wu L, Hunt S, and Brinton E. (2005) Plasma TG and type IIIhyperlipidemia are independently associated with premature familial coronaryartery disease J. Am. Coll. Cardiol.;45;1003-1012,
  31. Yamaguchi T, Horio F, Hashizume T, Tanaka M, Ikeda S, Kakinuma A,Nakajima H. (1995). Bilirubin is oxidized in rats treated with endotoxin and actsas a physiological antioxidant synergistically with ascorbic acid in vivo. BiochemBiophys Res Commun, 214:11.9.
  32. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. (2004)Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk:the role of nicotinic acid.a position paper developed by the EuropeanConsensus Panel on HDL-C. Curr Med Res Opin.20(8):1253-1268.

Corresponding Author

Dr Rajeeb Kalita

Assistant Professor, Dept. of Biochemistry,

Bundelkhand Medical College, Sagar, Madhya Pradesh,

Pin 470001 INDIA